Comparative antihypertensive effectiveness of once-daily mibefradil and diltiazem CD

This publication has 15 references indexed in Scilit:

• The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect
  Journal of Human Hypertension, 1997
• Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
  American Journal of Hypertension, 1997
• Additional Antianginal and Anti-Ischemic Efficacy of Mibefradil in Patients Pretreated With a Beta Blocker for Chronic Stable Angina Pectoris
  The American Journal of Cardiology, 1997
• Hemodynamic and Cardiac Effects of the Selective T-Type and L-Type Calcium Channel Blocking Agent Mibefradil in Patients With Varying Degrees of Left Ventricular Systolic Dysfunction
  Journal of the American College of Cardiology, 1996
• Antihypertensive Properties of the Novel Calcium Antagonist Mibefradil (Ro 40-5967)
  Hypertension, 1996
• Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study
  American Heart Journal, 1995
• The binding interactions of Ro 40-5967 at the L-type Ca2+ channel in cardiac tissue
  European Journal of Pharmacology, 1995
• Selective inhibition of T-type Ca2+ channels by Ro 40-5967.
  Circulation Research, 1994
• The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts
  Cardiovascular Drugs and Therapy, 1990
• In Vitro Pharmacologic Profile of Ro 40-5967, a Novel Ca2+ Channel Blocker with Potent Vasodilator but Weak Inotropic Action
  Journal of Cardiovascular Pharmacology, 1989